If you are interested in tests that we do not offer in our
exhaustive list, please contact us
- we have the possibility of proposing new tests upon request.
Analysis name |
OMIM |
Gene |
Mutation |
Technique |
Duration |
Material to be sent |
Test accreditation / EQA |
Laboratory accreditation / EQA |
Price (Euros) |
Achondroplasia |
100800 |
FGFR3 |
c.1138G>A; c.1138G>C |
Sequencing |
20 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
290 |
Acute Myeloid Leukemia M1, M2 |
|
FLT - 3 |
Internal Tandem Duplication and Mutation D835 |
PCR |
5 days |
4 micrograms DNA |
|
ISO 15189 |
290 |
Acute Myeloid Leukemia, Mast Cell Leukemia, mastocytosis |
|
c - KIT |
mutations in exons 8, 11 and 17 |
PCR and Sequencing |
12 days |
4 micrograms DNA |
|
|
460 |
Acyl - CoA dehydrogenase medium chain deficiency |
201450 |
MCAD |
mutation A985G |
PCR and RFLP |
1 month |
2 micrograms DNA |
|
|
170 |
Adenomatosous polyposis of the colon |
175100 |
APC |
whole gene |
Sequencing |
20-30 days |
2 micrograms DNA |
|
|
650 |
Adenomatosous polyposis of the colon |
|
MYH |
Sequencing |
Sequencing |
|
2 micrograms DNA |
|
|
1330 |
Adult Polycistic Kidney Disease |
#173900 |
PKD1 |
linkage analysis |
microsatellites |
30 - 60days |
4 micrograms DNA |
|
UNI EN ISO 9001 - CERMET / EMNQ, Istituto Superiore Sanità |
880 |
Adult polycystic kidneys - PKD1, PKD2 |
173900 |
PKD1, PKD2 |
2 whole genes |
Sequencing |
3 months |
2 micrograms DNA |
CLIA |
CLIA |
3900 |
Alagille syndrome |
118450 |
JAG1 |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
3500 |
Alpha - galactosidase A (GLA) |
301500 |
GLA |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL, CAP |
770 |
Alpha - thalassemia |
141800 |
HBA |
deletion 3,7 KB |
RFLP's |
25 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
290 |
Alpha - thalassemia |
#141750 |
HBA2, Alpha Globin |
del 3,7 Kb MED del 4,2 Kb del 20,5 Kb HphI NcoI |
DNA extraction + amplification + hybridization |
15 days |
2 micrograms DNA |
|
|
190 |
Alpha - thalassemia deletion 3,7 Kb |
#141750 |
HBA2, Alpha Globin |
del 3,7 Kb |
DNA extraction + amplification + electrophoresis |
15 days |
2 micrograms DNA |
|
|
148 |
Alpha - thalassemias |
141800 |
Alpha - GLOBIN GENES |
3,7/ 20,5/ Med deletions |
Multiplex PCR |
2 weeks |
2 micrograms DNA |
|
CAP |
290 |
Alpha 1 antitrypsin deficiency |
107400 |
PI |
HAPLOtype |
RFLP's |
20 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
440 |
Alport syndrome, autosomal recessive |
203780 |
COL4A3 + COL4A4 |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
15000 |
Alport syndrome, X - linked |
301050 |
COL4A5 |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
8880 |
Alzheimer disease I - (AD1) |
104760 |
APP |
point mutation |
PCR - SSCP - DNA Sequencing |
3 days |
2 micrograms DNA |
|
CAP |
490 |
Alzheimer disease II - (AD2) |
104310 |
APOE |
E2,E3,E4 alleles |
PCR - RFLP |
3 days |
2 micrograms DNA |
|
CAP |
130 |
Alzheimer disease II - all coding exons |
104760 |
APP |
all coding exons |
Sequencing |
20 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
550 |
Alzheimer disease PSN1 |
104311 |
PSN1 |
regulatory region + entire coding region |
Sequencing |
20 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
4400 |
Alzheimer disease PSN2 |
104300 |
PSN2 |
all coding exons |
Sequencing |
20 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
380 |
Alzheimer, early onset, AD3 |
104310 |
Apo E |
HAPLOtype |
RFLP's |
15 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
290 |
Alzheimer, early onset, AD3 |
104311 |
PSEN1 |
whole gene |
Sequencing |
45 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
770 |
Amino acid transporter responsible for LPI (SLC7A7) |
603593 |
LPI |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
980 |
Amyotrophic Lateral Sclerosis, ALS1 |
#105400 |
SOD1 |
mutations |
polymerase chain reaction sequence analysis |
10 days |
4 micrograms DNA |
|
UNI EN ISO 9001 - CERMET / EMNQ, Istituto Superiore Sanità |
770 |
Angelman syndrome |
105830 |
UBE3A |
all coding exons |
Sequencing |
|
2 micrograms DNA |
|
ISO 2001 |
1200 |
Angiotensin I - converting enzyme (ACE) |
106180 |
ACE1, DCP1 |
Fragment analysis |
Fragment analysis |
2 - 4 weeks |
2 micrograms DNA |
DGKL |
DGKL,CAP |
150 |
Anion exchange protein (1SLC4A1) |
109270 |
BND3, EMPB3, EPB3, AE1 |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
1100 |
Antithrombin 3 (SERPINC1) |
107300 |
AT3, AT - III |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
590 |
Antithrombin Deficiency |
107300 |
SERPINC1 |
Analysis for known mutations |
usually PCR & Sequencing |
10 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
320 |
Antithrombin Deficiency |
107300 |
SERPINC1 |
Full gene analysis |
dHPLC & Sequencing |
30 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
880 |
Apert syndrome |
101200 |
FGFR2 |
M (S225W, P253R) |
Sequencing Ex8 ex10 |
< 2 months |
2 micrograms DNA |
|
in preparation |
400 |
Apert syndrome Acrocephalosyndactylya type I |
#101200 |
FGFR2 |
S252W/ F P253R |
DNA extraction + amplification + sequence |
20 days |
2 micrograms DNA |
|
|
330 |
Apolipoprotein B - 100 Deficiency |
107730 |
APOB 100 |
R3500Q, R3500W, R3531C |
Sequencing |
4 days |
2 micrograms DNA |
|
|
175 |
Apolipoprotein C2(APOC2) |
207750 |
APOC2 |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
450 |
Aquaporin 2(AQP2) |
107777 |
|
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
450 |
Arginine vasopressin receptor 2 (AVPR2) |
300538 |
ADHR, V2R, V2 |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
490 |
Ashkenazi Jewish diseases panel |
|
HEX A, BLM, ASPA, SMPD1, IKBKAP, DYT1, MCOLN1, FANCC, F11, G6PC, BCKHDB, GJB2, MEFV, GDE (or Amylo-1,6-glucosidase), GBA and CFTR. |
83 mutations |
PCR and APEX |
1 month |
2,5 micrograms DNA |
|
ISO 9001:2000 |
390 |
Autosomal Dominant Retinitis Pigmentosa |
600105, 608380 |
Ca4, FSCN2, IMPDH1, NRL, PRPF3, PRPF31, PRPF8, RDS, RHO, ROM1, RP1, RP9, CRX |
341 positions |
PCR and APEX |
1 month |
2,5 micrograms DNA |
|
|
390 |
Autosomal Recessive Retinitis Pigmentosa |
|
CERKL, CNGA1, CNGB1, MERTK, PDE6A, PDE6B, PNR, RDH12, RGR, RLBP1, SAG, TULP1, CRB, RPE65, USH2A, USH3A |
|
PCR and APEX |
1 month |
6 micrograms DNA |
|
|
390 |
Azoo - oligozoospermia |
400003 |
Yq11 |
Y deletion |
PCR (promega Y deletion kit) |
6 - 8 weeks |
2 micrograms DNA |
EMQN |
in preparation |
400 |
Azoospermia_deletions (AZF regions) - microdeletions |
400003 |
DAZ, KALY, RBM |
microdeletions |
Multiplex PCR |
1 week |
2 micrograms DNA |
|
CAP |
380 |
Bardet Biedl Syndrome |
|
BBS1, BBS2, BBS3, BBS4, BBS5, BBS6, BBS7, BBS8, BBS9, BBS10, PHF6, ALMS1, GNAS1 |
248 mutations |
PCR and APEX |
1 month |
4 micrograms DNA |
|
ISO 9001:2000 |
450 |
Barth syndrome |
302060 |
TAZ |
|
point mutation analysis |
|
2 micrograms DNA |
|
|
1100 |
Beare - Stevenson syndrome |
#123790 |
FGFR2 |
S372C Y375C |
DNA extraction + amplification + sequence |
20 days |
2 micrograms DNA |
|
|
240 |
Becker Muscular Dystrophy (BMD) |
300 376 310 200 |
Dystrophin |
exon 3, 4, 6, 8, 12, 13, 16, 17, 19, 32, 34, 41, 42, 43, 44, 45, 47, 48, 49, 50, 51, 52, 60, pb pm |
Multiplex PCR |
1 month |
2 micrograms DNA |
EMQN - 2005 |
|
400 |
Beckwith - Wiedemann |
130650 |
CDKNC1 (p57) |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
|
ISO 2001 |
750 |
Beckwith - Wiedemann |
130650 |
H19 |
methylation |
|
30 days |
2 micrograms DNA |
|
ISO 2001 |
290 |
Beckwith - Wiedemann |
130650 |
LIT 1 |
methylation |
|
30 days |
2 micrograms DNA |
|
ISO 2001 |
290 |
Beckwith - Wiedemann |
130650 |
|
microsatellite in 11p15.5 |
|
30 days |
2 micrograms DNA |
|
ISO 2001 |
390 |
Bernard - Soulier syndrome |
231200 |
GP1BA, GP1BB & GP9 |
Analysis for known mutations |
usually PCR & Sequencing |
10 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
320 |
Bernard - Soulier syndrome |
231200 |
GP1BA, GP1BB & GP9 |
Full gene analysis |
dHPLC & Sequencing |
60 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
1900 |
Beta - thalassemia |
#603902 |
HBB, Beta - Globin |
Exon 1 + 2 + 3 Intron 1 + 2 |
DNA extraction + amplification + sequence |
15 days |
2 micrograms DNA |
|
|
220 |
Beta Thalassemia |
191901 |
Beta Thalassemia |
whole gene |
Sequencing |
10 days |
2 micrograms DNA |
|
|
345 |
Bloom Syndrome |
210900 |
BLM |
BLM-ASH |
ASO |
3 weeks |
5 micrograms DNA |
NYS-DOH |
CLIA NYS-DOH CAP |
1-20 samples a month 135; 21-100 samples a month 115; over 100 samples a month 95 |
Breast and Ovarian cancer (BRCA1 and BRCA2) |
113705, 600185 |
BRCA 1 and BRCA 2 full genes screening |
TGCE (Temperature Gradient Capillary Electrophoresis; Transgenomics Inc.) + analysis of all exons and exons - introns boundaries with bidirectional sequencing of all variant profiles + MLPA (Multiplex Ligation-dependent Probe Amplification; MRC Holland) for major deletions or insertions. |
|
2 months |
2 micrograms DNA |
EMQN |
EMQN |
1200 Euro for 0 - 10 samples per month; 1150 Euro for 11 to 100 samples per month; 950 Euro for 101 samples per month and above |
Breast and Ovarian cancer (BRCA1) |
113705 |
BRCA1 |
whole gene |
Sequencing + MLPA |
20-30 days |
2 micrograms DNA |
|
|
650 |
Breast and Ovarian cancer (BRCA2) |
600185 |
BRCA2 |
whole gene |
Sequencing + MLPA |
20-30 days |
2 micrograms DNA |
|
|
650 |
Brugada syndrome |
601144 |
SCN5A |
Mutation hotspots |
Sequencing |
|
2 micrograms DNA |
ISO 17025 |
ISO 17025 |
3500 |
Calcium sensing receptor (CASR) |
601199 |
PCAR1 |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
770 |
Canavan Disease |
271900 |
ASPA |
E285A, Y231X |
ASO |
3 weeks |
5 micrograms DNA |
NYS-DOH |
CLIA NYS-DOH CAP |
1-20 samples a month 135; 21-100 samples a month 115; over 100 samples a month 95 |
Carbonic anhydrase 2(CA2) |
259730 |
CA II |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
590 |
Cardiofaciocutaneus syndrome, CFC |
115150 |
BRAF |
mutation screening of exons 6,11,12 |
CSGE + Sequencing |
30 days |
5 micrograms DNA |
|
EMQN |
650 |
Cardiovascular and Alzheimer's risk - C112R, R158C |
107741 |
APOE |
C112R, R158C |
Sequencing |
20 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
190 |
Cardiovascular risk |
602601 |
LOX1, - 188C - T |
allelic variant |
polymerase chain reaction reverse dot blot hybridisation |
7 days |
4 micrograms DNA |
|
UNI EN ISO 9001 - CERMET / EMNQ, Istituto Superiore Sanità |
220 |
Cardiovascular risk - Cys112Arg, Arg158Cys, Arg3500Gln |
107741 |
APOE + APOB |
Cys112Arg, Arg158Cys, Arg3500Gln |
PCR and reverse hybridization |
2 weeks |
2 micrograms DNA |
|
|
260 |
Carnitine Palmitoyltransferase II |
650 |
CPTII |
all coding exons |
Sequencing (all coding exons) |
< 2 months |
2 micrograms DNA |
|
in preparation |
800 |
Cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy (CADASIL) |
125310 |
HOTCH3 |
whole gene |
Sequencing |
3 months |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
2400 |
Ceroid lipofuscinosis neuronal 3 juvenile Batten disease (CLN3) |
204200 |
CLN3 |
exons 7 - 8 deletion |
PCR |
1 month |
2 micrograms DNA |
|
|
210 |
Ceroid Lipofuscinosis, neuronal type 6 |
601780 |
CLN6 |
all coding exons |
Sequencing (all coding exons) |
2 - 4 months |
2 micrograms DNA |
|
in preparation |
800 |
Charcot - Marie - tooth 1A |
118220 |
PMP22 |
whole gene |
Sequencing |
45 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
890 |
Charcot - Marie - tooth 1B |
118200 |
MPZ |
whole gene |
Sequencing |
45 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
1390 |
Charcot - Marie - tooth 1E |
118300 |
PMP22 |
whole gene |
Sequencing |
45 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
990 |
Charcot - Marie - tooth 2I |
607677 |
MPZ |
whole gene |
Sequencing |
45 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
1390 |
Charcot - Marie - tooth 2J |
607736 |
MPZ |
whole gene |
Sequencing |
45 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
1390 |
Charcot - Marie - tooth disease type 1D |
607678 |
EGR2 |
all coding exons |
Sequencing |
20 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
1100 |
Charcot - Marie - tooth disease type 4A |
214400 |
GDAP1 |
all coding exons |
Sequencing |
20 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
700 |
Charcot - Marie - tooth disease type 4D |
601455 |
NDRG1 |
Lom mutation |
Sequencing |
20 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
440 |
Chemokine receptor (CCR5) |
601373 |
CMKBR5 |
deletion CCR5D32 |
PCR |
1 month |
2 micrograms DNA |
|
|
210 |
Chloride channel 5 (CLCN5) |
300008 |
CLCK2, K2, CLC5 |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
1440 |
Chronic Myelomonocytic Leukemia (CMML) , Essential Thrombocythemia, Hypereosinophilic syndrome, Myeloid metaplasia with myelofibrosis, Neutrophilic Leukemia (CNL) , Polycythemia vera, Systemic Mastocytosis, Myelodysplastic syndromes |
|
JAK2 |
mutation V617F |
4 - primer ARMS PCR |
5 days |
4 micrograms DNA |
|
ISO 15189 |
175 |
Chronic progressive external ophthalmoplegia (CPEO) |
590055 |
MTTL2 |
deletions |
|
1 week |
2 micrograms DNA |
|
|
165 |
CMTX - GJB1 - all coding exons |
302800 |
GJB1 |
all coding exons |
Sequencing |
20 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
550 |
Coffin Lowry syndrome |
303600 |
RSK2 |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
3250 |
Collagen type IV, Alpha 3 (COL4A3) |
120070 |
COL4A3 |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
1750 |
Collagen type IV, Alpha 4 (COL4A4) |
120131 |
COL4A4 |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
1750 |
Collagen type IV, Alpha 5 (COL4A5) |
303630 |
COL4A5 |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
1750 |
Combined FV & FVIII Deficiency |
227300 |
LMAN1 & MCFD2 |
Analysis for known mutations |
usually PCR & Sequencing |
10 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
320 |
Combined FV & FVIII Deficiency |
227300 |
LMAN1 & MCFD2 |
Full gene analysis |
dHPLC & Sequencing |
60 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
1800 |
Complement factor H (CFH) |
134370 |
HF1, HF, FHL1 |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
1980 |
COMT activity |
116790 |
COMT |
Val158Met |
PCR - RFLP |
1 week |
2 micrograms DNA |
|
CAP |
190 |
Congenital adrenal hyperplasia |
201910 |
CYP21 |
all coding exons |
Sequencing (all coding exons) , SB |
2 - 4 months |
2 micrograms DNA |
|
in preparation |
800 |
Cornelia De Lange syndrome |
122470 |
NIPBL |
all coding exons |
DHPLC |
30 days |
2 micrograms DNA |
|
ISO 2001 |
790 |
Coronary disease - ACE - Insertion/ deletion |
106180 |
ACE |
Insertion/ deletion |
PCR - ASO |
3 days |
2 micrograms DNA |
|
CAP |
350 |
Coronary spasm susceptibility |
163729 |
ecNOS |
788C/ T, 894 G/ T & intron 4 VNTR |
PCR - ASO |
2 weeks |
2 micrograms DNA |
|
CAP |
80 |
Crouzon syndrome |
123500 |
FGFR2 |
exons 8, 10 |
Sequencing (exons 8, 10) |
2 - 4 months |
2 micrograms DNA |
|
in preparation |
400 |
CYP27B1 (25 - hydroxyvitaminD3 1 - Alpha - hydroxylase gene) |
264700 |
P450C1 - Alpha, CYP1, VDDR, PDDR, VDD1, CP2B, CYP27B, P450C1, VDDRI, VDDRII |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL, CAP |
770 |
CYP2C19 |
124029 |
CYP2C19 |
CYP2C19*2, 3 |
PCR - RFLP |
2 weeks |
2 micrograms DNA |
|
CAP |
380 |
CYP3A5 |
605325 |
CYP3A5 |
CYP3A5*1, 2, 3 |
PCR - ASO |
2 weeks |
2 micrograms DNA |
|
CAP |
190 |
Cystathionine b - Synthase (CBS) gene |
236200 |
CBS |
Analysis for known mutations |
usually PCR & Sequencing |
10 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
320 |
Cystathionine b - Synthase (CBS) gene |
236200 |
CBS |
Full gene analysis |
dHPLC & Sequencing |
40 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
1600 |
Cystic fibrosis (33 mutations + poly T) |
219700 |
CFTR/ ABCC7 |
33 common mutation + poly T: G85E; 394delTT; 621+1G?T; R117H; I148T; 711+1G?T; 1078delT; R347P; R347H; R334W; Polimorfismo Poly-T; A455E; DI507; DF508; 1717-1G?A; V520F; G542X; S549N; S549R; G551D; R553X; R560T; 1898+1 G?A; 2183AA?G; 2184delA; 2789 +5G?A; 3120+1 G?A ; R1162X; 3659delC; 3849+10KbC?T; 3876delA; W1282X; 3905insT; N1303K |
PCR/ OLA; ARMS - PCR |
7-10 days |
2 micrograms DNA |
CE marked kit, CF Consortium |
ISO 17025 / EMQN, CF Consortium, SAS |
155 |
Cystic fibrosis (CF and CBAVD) |
602421 |
CFTR |
246 positions |
PCR and APEX |
1 month |
2 micrograms DNA |
CF Network - 2004 |
|
390 |
Cystinuria gene (1SLC3A1) |
104614 |
ATR1, D2H, RBAT, CSNU, CSNU1 |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
980 |
Cystinuria gene 2 (SLC7A9) |
604144 |
CSNU3 |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
1290 |
Deafness Autosomal Dominant Nonsyndromic Sensorineural 9 |
601369 |
COCH |
P51S |
|
< 2 months |
2 micrograms DNA |
|
in preparation |
400 |
Deafness neurosensory, autosomal dominant low frequencies |
600965 |
WFS1 |
exon 8 |
Sequencing (exon 8) |
< 2 months |
2 micrograms DNA |
|
in preparation |
800 |
Deafness nonsyndromic (DFNB1) _(DFNA2) |
220 290 600 101 |
GJB2, GJB3, GJB6, GJA1, SLC26A5, SLC26A4, mtDNA |
201 mutations |
PCR and APEX |
1 month |
2 micrograms DNA |
|
|
390 |
Deafness, DFNA3 |
220290 |
GJB2 |
whole gene |
Sequencing |
45 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
990 |
Deafness, maternally inherited |
520000 |
DNA MITOCHONDRIAL |
A1555G |
RFLP's |
15 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
320 |
Dejernie - sottas (HMSNIII) , DSDA |
145900 |
PMP22 |
whole gene |
Sequencing |
45 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
990 |
Dejernie - sottas (HMSNIII) , DSDB |
145900 |
MPZ |
whole gene |
Sequencing |
45 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
1390 |
Dentatorubro - pallidoluyisian atrophy (DRPLA) |
125370 |
DRPLA |
REPEAT |
Fragments analysis |
30 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
540 |
Denys - Drash syndrome |
#194080 |
WT1 |
C360G R362X R366H H373Q H377Y R394W R394P D396G D396N |
DNA extraction + amplification + sequence |
20 days |
2 micrograms DNA |
|
|
320 |
Detection of high - risk types of HPVs in cervical cells |
603956 |
HPV |
|
DNA - Microarrays |
1 week |
2 micrograms DNA |
|
CAP |
180 |
DFNB1 |
121011 |
OGJB2 |
all coding sequence |
polymerase chain reaction sequence analysis restriction enzyme detection |
15days |
4 micrograms DNA |
|
UNI EN ISO 9001 - CERMET / EMNQ, Istituto Superiore Sanità |
775 |
Di George syndrome, velocardiofacial syndrome |
188400, 192430 |
|
|
fluorescent PCR |
prenatal: 2 weeks; postnatal: 4 weeks |
2 micrograms DNA |
|
|
1 person postnatal 250 - 3 persons postnatal 380 - only fetus 350 - fetus+parents 460 |
Di George, syndrome |
188400 |
REGION 22q11.2 |
deletion |
MLPA |
30 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
540 |
Dihydropyrimidine Dehydrogenase Deficiency (5 - Fluoro - Uracil Pharmacogenetics) |
274270 |
DPYD |
*2A (IVS14+ 1G>A) |
TaqMan |
3 - 5 days |
|
Medical University Graz |
EMQN, ÖQUASTA , DGKL , INSTAND |
90 |
DNA repair |
|
NAT1, NAT2, CYP2D6, CYP1B1, CYP1A1, CYP1A2, ATM, BRCA1, BRCA2, p16, CDKN1a, CDKN2A, etc..(106 genes) |
228 mutations |
PCR and APEX |
1 month |
13 micrograms DNA |
|
ISO 9001:2000 |
390 |
Duchenne Muscular Dystrophy (DMD) |
300 376 310 200 |
Dystrophin |
exon 3, 4, 6, 8, 12, 13, 16, 17, 19, 32, 34, 41, 42, 43, 44, 45, 47, 48, 49, 50, 51, 52, 60, pb pm |
Multiplex PCR |
1 month |
2 micrograms DNA |
EMQN - 2005 |
|
410 |
Dysautonomia |
223900 |
IKBKAP |
2507+ 6 T>C |
|
< 2 months |
2 micrograms DNA |
|
in preparation |
400 |
Dystonia, progressive with diurnal variation |
128230 |
DYT5 |
all coding exons |
Sequencing (all coding exons) |
2 - 4 months |
2 micrograms DNA |
|
in preparation |
800 |
Early - onset nephrotis syndrome Sclerosis mesangial diffuse |
#256370 |
WT1 |
H377Y F383L D396N |
DNA extraction + amplification + sequence |
20 days |
2 micrograms DNA |
|
|
320 |
Ehlers Danlos type IV, vascular type |
130050 |
COL3A1 |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
2500 |
Epidermolysis bullosa dystrophica dominant |
131750 |
COL7A |
|
Sequencing |
3 months |
2 micrograms DNA |
|
|
4300 |
Epidermolysis bullosa dystrophica recessive |
226600 |
COL7A1 |
whole gene |
Sequencing |
3 months |
2 micrograms DNA |
|
|
4300 |
Epidermolysis bullosa dystrophica with subcorneal cleavage |
607600 |
COL7A1 |
whole gene |
Sequencing |
3 months |
2 micrograms DNA |
|
|
4300 |
Epidermolysis bullosa pretibial |
131850 |
COL7A1 |
whole gene |
Sequencing |
3 months |
2 micrograms DNA |
|
|
4300 |
Epidermolysis bullosa pruriginosa, autosomal dominant and recessive |
604129 |
COL7A1 |
whole gene |
Sequencing |
3 months |
2 micrograms DNA |
|
|
4300 |
Epidermolysis bullosa with congenital localized absence of skin and deformity of nails |
132000 |
COL7A1 |
whole gene |
Sequencing |
3 months |
2 micrograms DNA |
|
|
4300 |
Epithelial sodium channel, beta subunit (SCNN1B) |
600760 |
SCNEB |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
1290 |
Epithelial sodium channel, gamma subunit (SCNN1G) |
600761 |
SCNEG |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
1290 |
ERCC1 |
*126380 |
ERCC1 |
Asn118Asn |
Sequencing |
1 week |
2 micrograms DNA |
|
|
110 |
ERCC2_XPD - Asp312Asn |
#278730 |
ERCC2/ XPD |
Asp312Asn |
Sequencing |
1 week |
2 micrograms DNA |
|
|
110 |
ERCC2_XPD - Lys751Gln |
#278730 |
ERCC2/ XPD |
Lys751Gln |
Sequencing |
1 week |
2 micrograms DNA |
|
|
110 |
Exostoses Multiple type I |
133700 |
EXT1 |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
2400 |
Exostoses Multiple type II |
133700 |
EXT2 |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
2600 |
Factor V Deficiency |
227400 |
F5 |
Analysis for known mutations |
usually PCR & Sequencing |
10 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
320 |
Factor V Deficiency |
227400 |
F5 |
Full gene analysis |
dHPLC & Sequencing |
40 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
2800 |
Factor VII Deficiency |
227500 |
F7 |
Analysis for known mutations |
usually PCR & Sequencing |
10 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
320 |
Factor VII Deficiency |
227500 |
F7 |
Full gene analysis |
dHPLC & Sequencing |
30 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
1100 |
Factor X Deficiency |
227600 |
F10 |
Analysis for known mutations |
usually PCR & Sequencing |
10 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
320 |
Factor X Deficiency |
227600 |
F10 |
Full gene analysis |
dHPLC & Sequencing |
30 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
1100 |
Factor XI Deficiency |
264900 |
F11 |
Analysis for known mutations |
usually PCR & Sequencing |
10 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
320 |
Factor XI Deficiency |
|
F11 |
Ashkenazi Jewish type II & type III mutations |
PCR & Sequencing |
20 days |
2 micrograms DNA |
|
|
430 |
Factor XI Deficiency |
264900 |
F11 |
Full gene analysis |
dHPLC & Sequencing |
30 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
980 |
Factor XII |
134570 |
F12 |
C46CT |
|
20 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
290 |
Familial adenomatous polyposis coli, MYH, MUTYH associated Polyposis (MAP) |
*604933 |
MUTYH |
Sequencing |
Sequencing |
|
2 micrograms DNA |
|
|
1330 |
Familial dysautonomia |
223900 |
IKBKAP |
2507+ 6 T>C |
RFLP |
3 weeks |
5 micrograms DNA |
NYS-DOH |
CLIA NYS-DOH CAP |
1-20 samples a month 135; 21-100 samples a month 115; over 100 samples a month 95 |
Familial gastric cancer diffuse |
192090 |
CDH1 |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
6500 |
Familial Hypercholesterolemia |
114010 |
LDL + ApoB |
208 MUTATION + Sequencing+ REARRANGEMENTS |
Microarrays+ Sequencing |
2 months |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
1900 |
Familial Hypercholesterolemia (Apolipoprotein E isoforms) |
107741 |
APOE |
e2/ e3/ e4 subtypes |
TaqMan |
3 - 5 days |
2 micrograms DNA |
ÖQUASTA , DGKL |
EMQN, ÖQUASTA , DGKL , INSTAND |
90 |
Familial Hypercholesterolemia (Defective Apolipoprotein B) |
144010 |
APOB |
R3500Q |
TaqMan |
3 - 5 days |
2 micrograms DNA |
ÖQUASTA, DGKL |
EMQN, ÖQUASTA , DGKL , INSTAND |
100 |
Familial hyperinsulinism |
256450 |
ABCC8 |
IVS32-9G>A, deltaF1388 |
RFLP |
3 weeks |
5 micrograms DNA |
NYS-DOH |
CLIA NYS-DOH CAP |
1-20 samples a month 135; 21-100 samples a month 115; over 100 samples a month 95 |
Familial malignant melanoma |
155601 |
p16 (CDKN2A) |
whole gene |
Sequencing |
20-30 days |
2 micrograms DNA |
|
|
440 |
Familial meditarranean fever |
608107 |
MEFV |
E148Q |
RFLP's |
20 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
290 |
Familial meditarranean fever |
608107 |
MEFV |
exon 10 |
Sequencing |
30 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
390 |
Familial Mediteranean Fever (MEFV) |
249100 |
(MEFV) |
whole gene |
Sequencing |
20 days |
2 micrograms DNA |
|
|
450 |
Familial Mediterranean Fever |
249100 |
MEFV |
10 mutations M680I, V726A, M694V, M694I, K695R, A744S, R761H, 692delI, A653H y A408G |
Sequencing |
20 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
440 |
Familial mediterranean fever Recurrent polyserositis Familial paroxismal polyserositis |
#249100 |
MEFV |
E148Q E148V E163A E319K I591T M694V E319K I591T M694V |
DNA extraction + amplification + sequence |
20 days |
2 micrograms DNA |
|
|
320 |
Familial spastic paraplegia type I |
|
L1CAM |
|
DNA extraction + amplification + sequence |
30 days |
2 micrograms DNA |
|
|
580 |
Familial spastic paraplegia type II SPG2, SPPX2 |
#312920 |
PLP1 (lipophilin) |
H139Y S169F F236S I186T |
DNA extraction + amplification + sequence |
30 days |
2 micrograms DNA |
|
|
580 |
Familial spastic paraplegia type III SPG3 Strumpell Disease |
#182600 |
SPG3A (atlastin) |
R217Q R239C |
DNA extraction + amplification + sequence |
2 months |
2 micrograms DNA |
|
|
580 |
Familial spastic paraplegia type IV SPG4 |
#182601 |
SPG4 (spastin) |
S44L P45Q K299X 344K S362C N386S D441G C448Y D470V T1520del R499C AÆG nt 1620 Expansion (CAG) n R562E A578ins GÆC 1853+ 1IVS 9+ 4 AÆG 1 bp ins |
DNA extraction + amplification + sequence |
5 months |
2 micrograms DNA |
|
|
2400 |
Familial spastic paraplegia type VI SPG6 |
#600363 |
NIPA1 |
T45R |
DNA extraction + amplification + sequence |
30 days |
2 micrograms DNA |
|
|
250 |
Familial spastic paraplegia type VII SPG7 |
#607259 |
SPG7 (paraplegin) |
784 del 2 bp A2228del 9,5 Kb del |
DNA extraction + amplification + sequence |
30 days |
2 micrograms DNA |
|
|
400 |
Familial spastic paraplegia type X SPG10 |
#604187 |
KIF5A |
N256S R280C |
DNA extraction + amplification + sequence |
30 days |
2 micrograms DNA |
|
|
275 |
Familial spastic paraplegia type XIII SPG13 |
#605280 |
HSP60 (chaperonin) |
V72I |
DNA extraction + amplification + sequence |
30 days |
2 micrograms DNA |
|
|
275 |
Familial spastic paraplegia type XVII SPG17 Silver syndrome |
#270685 |
BSCL2 (seipin) |
N88S S90L |
DNA extraction + amplification + sequence |
30 days |
2 micrograms DNA |
|
|
275 |
Familial spastic paraplegia type XXI SPG21 |
|
ACP33 (maspardin) |
A601ins |
DNA extraction + amplification + sequence |
30 days |
2 micrograms DNA |
|
|
275 |
Fanconi anemia complementation group C |
227645 |
FACC |
IVS4+ 4A>T |
ASO |
3 weeks |
5 micrograms DNA |
NYS-DOH |
CLIA NYS-DOH CAP |
1-20 samples a month 135; 21-100 samples a month 115; over 100 samples a month 95 |
Fibrinogenaemia (Dys - , Hypo - and A) |
202400 |
FGA, FGB & FGG |
Analysis for known mutations |
usually PCR & Sequencing |
10 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
320 |
Fibrinogenaemia (Dys - , Hypo - and A) |
202400 |
FGA, FGB & FGG |
Full gene analysis |
dHPLC & Sequencing |
60 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
3400 |
Follicular Lymphoma |
|
BCL2/ JH t(14; 18) translocation |
|
PCR |
5 days |
4 micrograms DNA |
|
ISO 15189 |
290 |
Fragile site rare (FRAXE) |
309548 |
FMR - 2 |
repeats |
|
2 weeks |
2 micrograms DNA |
|
|
170 |
Frasier syndrome |
#136680 |
WT1 |
R390X F392L |
DNA extraction + amplification + sequence |
20 days |
2 micrograms DNA |
|
|
320 |
Galactosemia |
#230400 |
GALT |
(all coding sequence) |
polymerase chain reaction sequence analysis restriction enzyme detection |
7 - 10days |
4 micrograms DNA |
|
UNI EN ISO 9001 - CERMET / EMNQ, Istituto Superiore Sanità |
770 |
Galactosemia |
230400 |
GALT |
mutation Q188R |
PCR and RFLP |
1 month |
2 micrograms DNA |
|
|
210 |
Gaucher Disease |
230800 |
GBA |
R496H, N370S, 84GG, L444P, IVS2+1 |
ASO |
3 weeks |
5 micrograms DNA |
NYS-DOH |
CLIA NYS-DOH CAP |
1-20 samples a month 135; 21-100 samples a month 115; over 100 samples a month 95 |
Gaucher Disease (GBA) |
230800 |
GBA |
whole gene |
Sequencing |
7-10 days |
2 micrograms DNA |
|
|
850 |
Gefitinib resistance |
*131550 |
EGFR |
exon 18 - 21 |
TGCE |
3 weeks |
2 micrograms DNA |
|
|
300 |
Gene of autosomal recessive hypercholesterolemia (LDLRAP1) |
605747 |
ARH, ARH1, ARH2, FHCB1, FHCB2, MGC34705 |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
980 |
Glanzmann Thrombasthenia |
273800 |
ITGA2B & ITGB3 |
Analysis for known mutations |
usually PCR & Sequencing |
10 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
320 |
Glanzmann Thrombasthenia |
273800 |
ITGA2B & ITGB3 |
Full gene analysis |
dHPLC & Sequencing |
60 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
2200 |
Glaucoma congenital |
231300 |
CYP1B1 |
all coding exons |
Sequencing (all coding exons) |
2 months |
2 micrograms DNA |
|
in preparation |
800 |
Glucokinase (GCK) |
138079 |
GK, GLK, HK4 |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
1100 |
Glutathion - S - transferase M1 |
138350 |
GSTM1 |
deletion |
|
1 week |
2 micrograms DNA |
|
|
195 |
Glutathion - S - transferase T1 |
600436 |
GSTT1 |
deletion |
|
1 week |
2 micrograms DNA |
|
|
195 |
Glycogen storage disease, type 1a |
232200 |
GSD1A |
R83C |
RFLP |
3 weeks |
5 micrograms DNA |
NYS-DOH |
CLIA NYS-DOH CAP |
1-20 samples a month 135; 21-100 samples a month 115; over 100 samples a month 95 |
GNAS complex locus (GNAS1) |
139320 |
GNAS, NESP55, GS, XLAS, ALEX |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
1500 |
Goldmann - Favre syndrome |
268100 |
NR2E3 |
all coding exons |
Sequencing (all coding exons) |
2 - 4 months |
2 micrograms DNA |
|
in preparation |
800 |
gonadal dysgenesis, XY female type; GDXY |
306100 |
SRY |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
990 |
gonadal dysgenesis, XY female type; GDXY |
306100 |
SRY |
presence/ absence |
PCR |
20 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
440 |
Gorlin - Goltz syndrome |
109400 |
PTCH |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
2700 |
Growth hormone 1(GH1) |
139250 |
GH, GHN, GHD |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
490 |
Haemophilia |
|
F8 |
Analysis for known mutations |
usually PCR & Sequencing |
10 days |
2 micrograms DNA |
UK NEQAS Haemophilia Genetics |
|
320 |
Haemophilia |
|
F8 |
IVS 22 & IVS 1 Inversions |
Direct detection by PCR |
20 days |
2 micrograms DNA |
UK NEQAS Haemophilia Genetics |
|
430 |
Haemophilia A |
306700 |
F8 |
Full gene analysis |
dHPLC & Sequencing |
40 days |
2 micrograms DNA |
UK NEQAS Haemophilia Genetics |
CPA UK and UKHCDO |
1280 |
Haemophilia A |
306700 |
F8 |
Analysis for known mutations |
usually PCR & Sequencing |
10 days |
2 micrograms DNA |
UK NEQAS Haemophilia Genetics |
CPA UK and UKHCDO |
320 |
Haemophilia B |
306900 |
F9 |
Analysis for known mutations |
usually PCR & Sequencing |
10 days |
2 micrograms DNA |
UK NEQAS Haemophilia Genetics |
CPA UK and UKHCDO |
320 |
Haemophilia B |
306900 |
F9 |
Full gene analysis |
dHPLC & Sequencing |
20 days |
2 micrograms DNA |
UK NEQAS Haemophilia Genetics |
CPA UK and UKHCDO |
880 |
Heart block Familial |
113900 |
SCN5A |
Mutation hotspots |
Sequencing |
|
2 micrograms DNA |
ISO 17025 |
ISO 17025 |
3500 |
Hemochromatosis - C282 Y, H63D |
235200 |
HFE |
C282 Y, H63D |
PCR, RFLP, 3% agarose gel, TBE |
2 weeks |
2 micrograms DNA |
Internal quality control |
ISO 15189 |
80 |
Hemochromatosis - C282Y, H63D, S65C |
235200 |
HFE |
C282Y; H63D; S65C |
PCR - RFLP |
1 week |
2 micrograms DNA |
|
CAP |
190 |
Hemochromatosis - HFE Sequencing |
235200 |
HFE |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
EMQN 2005 |
ISO 17025:2005 / EMQN |
1100 |
Hemoglobin beta locus - HBB - Total gene Sequencing |
141900 |
HBB |
total gene |
Sequencing |
4 weeks |
2 micrograms DNA |
|
|
1900 |
Hemophila B ( IX FACTOR) |
306900 |
IX FACTOR |
whole gene |
Sequencing |
20 days |
2 micrograms DNA |
|
|
575 |
Hemophilia A - FVIII |
306700 |
FVIII |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
2200 |
Hemophilia A ( VIII FACTOR) |
306700 |
VIII FACTOR |
whole gene |
Sequencing |
30 days |
2 micrograms DNA |
|
|
675 |
Hemophilia B - FIX |
306900 |
FIX |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
1100 |
Hereditary Fructose Intolerance |
229600 |
ALDOB |
A149P, A174D, N334K |
TaqMan |
3 - 5 days |
|
|
EMQN, ÖQUASTA , DGKL , INSTAND |
150 |
Hereditary Fructose Intolerance |
229600 |
ALDOB |
all exons and exon - intron boundaries |
Sequencing of all exons and exon - intron boundaries |
3 - 4 weeks |
|
|
EMQN, ÖQUASTA , DGKL , INSTAND |
1100 |
Hereditary liability to pressure palsy (HNPP) |
159440 |
MPZ |
all coding exons |
Sequencing |
20 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
540 |
Hereditary Non Polyposis Colon Cancer (HNPCC) - MLH1 |
120436 |
MLH1 |
whole gene |
Sequencing + MLPA |
20-30 days |
2 micrograms DNA |
|
|
650 |
Hereditary Non Polyposis Colon Cancer (HNPCC) - MLH1, MSH2, MSH6 |
114400 |
MSH2, MLH1 and MSH6 full genes screening |
TGCE (Temperature Gradient Capillary Electrophoresis; Transgenomics Inc.) + analysis of all exons and exons - introns boundaries with bidirectional sequencing of all variant profiles + MLPA (Multiplex Ligation-dependent Probe Amplification; MRC Holland) for major deletions or insertions. |
|
2 months |
2 micrograms DNA |
EMQN |
EMQN |
1200 Euro for 0 - 10 samples per month; 1150 Euro for 11 to 100 samples per month; 950 Euro for 101 samples per month and above |
Hereditary Non Polyposis Colon Cancer (HNPCC) - MSH2 |
120435 |
MSH2 |
whole gene |
Sequencing + MLPA |
20-30 days |
2 micrograms DNA |
|
|
650 |
Hereditary Non Polyposis Colon Cancer (HNPCC) - PMS2 |
*120435 |
PMS2 |
Sequencing |
Sequencing |
|
2 micrograms DNA |
|
|
1280 |
Hereditary progressive dystonia |
128230 |
GTP - CHI |
point mutation |
PCR - SSCP - DNA |
3 weeks |
2 micrograms DNA |
|
CAP |
490 |
Homocystinuria |
603174 |
CBS |
exon 4, exon 8 |
Sequencing (exon 4, exon 8) |
< 2 months |
2 micrograms DNA |
|
in preparation |
400 |
HYDROXYLASE 21 - Deficiency |
201910 |
(CYP21A2) |
P30L Exon 1 - C -> T nucleotidic position 89; Pro ® Leu codon ; level 30 / A/C-655 ->G Intron 2 A/C -> G nucleotidic position 655 / N172I Exon 4 -T -> A nucleotidic position 999;Asn -> Ile codon level 172 / V281L Exon 7 G -> T nucleotidic position 1683; Val -> Leu codon level 281 / Q318X -Exon 8 C -> T nucleotidic position 1993;Gln ->Stop a codon level 318 / W356R Exon 8 C -> T nucleotidic position 2108; Trp -> Arg codon level 356. |
C -> T nucleotidic position 2108; Trp -> Arg codon level 356. |
15 days |
2 micrograms DNA |
|
|
345 |
Hypercholesterolemia |
#143890 |
LDLR |
D245E |
TGCE |
2 weeks |
2 micrograms DNA |
|
|
110 |
Hypertrophic Cardiomyopathy Familial |
192600 |
ACTC, MYL2, MYL3, MYH7, MYBPC3, TNNT2, TNNI3, TPM1 |
106 Exons |
Sequencing |
|
10 micrograms DNA |
CLIA |
CLIA |
3000 |
Hypobetalipoproteinemia Familial |
107730 |
APOB |
whole gene |
Sequencing |
3 months |
2 micrograms DNA |
ISO 17025 |
ISO 17025 |
4800 |
Hypochondroplasia |
146000 |
FGFR3 |
Sequencing |
Sequencing |
|
2 micrograms DNA |
|
|
2100 |
Hypochondroplasia - R3500Q, R3531C |
146000 |
FGFR3 |
R3500Q and R3531C |
Sequencing |
20 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
395 |
I factor (CFI ) |
217030 |
IF, FI, KAF, C3B - IN |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
1100 |
Ichthyosis congenita harlequin fetus type |
242500 |
ABCA12 |
whole gene |
Sequencing |
4 months |
2 micrograms DNA |
CLIA |
CLIA |
5700 |
Ichthyosis, X linked |
308100 |
Xp22.32 |
deletions |
MLPA |
25 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
440 |
Inclusion body myopathy |
600737 |
GNE |
all coding exons |
Sequencing (all coding exons) |
2 - 4 months |
2 micrograms DNA |
|
in preparation |
800 |
Incontinentia Pigmenti - Chromosome X inactivation |
308300 |
IKBKG |
Chromosome X inactivation |
|
20 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
395 |
Incontinentia Pigmenti - deletion exons 4 - 10 |
308300 |
IKBKG |
deletion exons 4 - 10 |
PCR |
20 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
395 |
Infantile Epilepsy, CDKL5 |
600185 |
CDKL5 |
|
PCR |
|
2 micrograms DNA |
|
|
980 |
Infantile spasm syndrome X - linked |
308350 |
ARX |
429 - 452dup en (GCG) 10+ 7 insertion |
|
< 2 months |
2 micrograms DNA |
|
in preparation |
400 |
Jackson - Weiss syndrome |
#123150 |
FGFR2 |
A344G |
DNA extraction + amplification + sequence |
20 days |
2 micrograms DNA |
|
|
240 |
k - ras activation |
#260350, #114500, #211980 |
KRAS2 |
codons 12, 13 |
TGCE |
2 weeks |
2 micrograms DNA |
|
|
110 |
Kearns - Sayre syndrome |
530000 |
POLG1, Twinkle, ANT1 |
|
|
|
2 micrograms muscle DNA |
|
|
290 |
Kostmann disease, Severe Congenital Neutropenia |
202700 |
ELA2 |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
990 |
Lactose Intolerance (adult type hypolactasia) |
223100 |
LCT |
- 13910T>C |
TaqMan |
3 - 5 days |
|
INSTAND |
EMQN, ÖQUASTA , DGKL , INSTAND |
90 |
LCHAD deficiency |
609016 |
HADHA |
mutation G1528C |
PCR and RFLP |
1 month |
2 micrograms DNA |
|
|
210 |
Leber congenital amaurosis (LCA1) |
204000 |
CRB1, AIPL1, GUCY2D, CRX, RPE65, RPGRIP1, MERTK, LRAT |
344 positions |
PCR and APEX |
1 month |
2 micrograms DNA |
|
|
390 |
Leber optic atrophia - G11778A |
516000 |
MTND1 |
G11778A |
|
1 week |
2 micrograms DNA |
|
|
280 |
Leber optic atrophy |
535000 |
mtDNA |
11778 G>A, 3460 G>A, 14484 T>C, 15257 A>G |
|
< 2 months |
2 micrograms DNA |
|
in preparation |
400 |
Leigh mitoncondrial syndrome |
516060 |
MTATP6 |
8993T>G y 8993TàC |
Sequencing |
20 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
290 |
Leopard syndrome |
151100 |
PTPN11 |
mutation screening of exons 2,3,4,7,8,12,13 |
CSGE + Sequencing |
30 - 40 days |
5 micrograms DNA |
|
EMQN |
890 |
Li - Fraumeni - Syndrom |
*151623 |
p53 |
whole gene |
Sequencing |
20-30 days |
2 micrograms DNA |
|
|
440 |
Lipoprotein lipase (LPL) |
238600 |
LIPD, FCHL |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
1100 |
Long QT syndrome 3 (LQT3) |
603830 |
SCN5A |
Mutation hotspots |
Sequencing |
|
2 micrograms DNA |
ISO 17025 |
ISO 17025 |
3500 |
Low density lipoprotein receptor LDLR |
143890 |
LOW DENSITY LIPOPROTEIN RECEPTOR |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
1880 |
Lowe syndrome |
309000 |
OCRL1 |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
3250 |
Lymphoma, Acute leukemia |
|
IgH gene rearrangement(VH - FR1 - 3 and DH1 - 7 to JH genes) |
|
multiplex PCR |
10 days |
4 micrograms DNA |
|
ISO 15189 |
400 |
Lymphoma, Acute leukemia |
|
TCR gamma (T cell receptor gamma) gene rearrangement (V?1 - 11genes to all J? exons: J?1.1/ 2.1 and J?1.3/ 2.3) |
|
multiplex PCR |
10 days |
4 micrograms DNA |
|
ISO 15189 |
400 |
Machado - Joseph Disease |
109150 |
ATX3 |
(repeat) |
PCR |
< 2 months |
2 micrograms DNA |
EMQN |
in preparation |
400 |
Male Infertility (Oligospermia - Azoospermia, Sertoli - cell - only syndrome) ) |
415000 |
AZFa AZFb AZFc (including DAZ and KALY) |
microdeletions |
multiplex PCR |
5 days |
2 micrograms DNA |
|
|
350 |
Male Infertility (Oligospermia - Azoospermia, Sertoli - cell - only syndrome) ) |
415000 |
AZFa, AZFb, AZFc |
microdeletions |
multiplex PCR |
5 days |
3 micrograms DNA |
|
ISO 15189 |
175 |
Maple syrup urine disease |
248611 |
BCKDHB |
R183P |
RFLP |
3 weeks |
5 micrograms DNA |
NYS-DOH |
CLIA NYS-DOH CAP |
1-20 samples a month 135; 21-100 samples a month 115; over 100 samples a month 95 |
Marfan type 1 syndrome |
154700 |
FBN1 |
Exons 13, 15, 21, 23, 24, 25, 26, 27, 28, 43, 44, 55, 62, 63 and 65 |
Sequencing |
30 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
2600 |
Marfan type 1 syndrome - all coding exons |
154700 |
FBN1 |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
8800 |
Marfan type 2 syndrome |
154705 |
TGFBR2 |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
1200 |
Marshall syndrome |
154780 |
COL11A1 |
whole gene |
Sequencing |
8 months |
10 micrograms DNA |
|
|
4000 |
May - Hegglin anomaly |
155100 |
MYH9 |
Analysis for known mutations |
usually PCR & Sequencing |
10 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
320 |
May - Hegglin anomaly |
|
MYH9 |
Analysis for known mutations |
usually PCR & Sequencing |
10 days |
2 micrograms DNA |
|
|
320 |
May - Hegglin anomaly |
155100 |
MYH9 |
Full gene analysis |
dHPLC & Sequencing |
40 days |
2 micrograms DNA |
|
CPA UK and UKHCDO |
4300 |
May - Hegglin anomaly |
|
MYH9 |
Targeted analysis - exons 25, 38 & 40 |
PCR & Sequencing |
20 days |
2 micrograms DNA |
|
|
750 |
Medullary thyroid carcinoma |
155240 |
RET |
Sequencing (exons 10, 11, 12, 13, 14, 16) |
Sequencing (exons 10, 11, 12, 13, 14, 16) |
2 - 4 months |
2 micrograms DNA |
|
in preparation |
800 |
MELAS - Mitochondrial myopathy encephalopathy lactic acidosis and strokelike episodes |
540000 |
MTTL1 |
all coding exons (3243A>G, 3271T>C y 3252A>G ) |
Sequencing |
20 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
395 |
Membrane cofactor protein (MCP) |
120920 |
CD46, MIC10, TLX, MGC26544, TRA2.10 |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
1250 |
Mental retardation 1 |
|
SWH, SCC, SLG, SW, SRT, SD, SK* |
deletions / DUPLICATIONS |
MLPA |
30 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
440 |
Mental retardation 2 |
|
DIGEORGE, SOTOS , KABUKI, ALAGILLE, |
deletions / DUPLICATIONS |
MLPA |
30 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
440 |
Mental retardation nonspecific (X-linked) MRX - Panel |
|
ARX, PQBP1, JARID1C, TM4SF2, FACL4, DLG3, FTSJ1 , ZNF41 |
|
Sequencing |
4 months |
2 micrograms DNA |
CLIA |
CLIA |
4000 |
Mental retardation X-linked |
|
X CHROMOSOME |
deletions / DUPLICATIONS |
MLPA |
30 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
440 |
Mental retardation, congenital anomalies |
|
|
Identification of submicroscopic gains and losses up to 3Mbp in cases with normal karyotype |
High Resolution Metaphase Comparative Genome Hybridization (HR - CGH) |
15 days |
10 micrograms DNA |
|
ISO 15189 |
460 |
MERRF - Myoclonic epilepsy associated with ragged - red fibers |
545000 |
MTTK |
8344A>G, 8356T>C y 8363G>A |
Sequencing |
20 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
395 |
Mineralocorticoid receptor (NR3C2) |
600983 |
MLR, HMR, MCR, MR |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
1450 |
Mitochondrial Panel 1 and Panel 2 : MELAS; MERRF; NARP; Cardiomyopathy & deafness; Diabetes & deafness; Leigh syndrome + MNGIE (multiple mtDNA deletions); Ocular and skeletal myopathy |
516060, 520000, 530000, 540000, 545000, 551500, 590060 |
mtDNA |
point mutations (A3243G, T3271C, A8344G, G8363A, T8993C, T8993G, T9176C, G13513A, T14709C), deletions |
PCR and ASO and/or RFLP and Southern blot hybridization |
2-3 weeks |
20 micrograms DNA (blood or muscle), muscle biopsy: 50 mg frozen |
|
CLIA |
1125; more than 25 samples a month 1025 |
Mitochondrial Panel 1 and Panel 2 expanded : MELAS; MERRF; NARP; Diabetes & deafness; Cardiomyopathy & deafness; Leigh syndrome + MNGIE (multiple mtDNA deletions); Ocular and skeletal myopathy; + KSS; Pearson's marrow - pancreas syndrome; PEO |
516060, 520000, 530000, 540000, 545000, 551500, 557000, 590060 |
mtDNA |
point mutations (A3243G, T3271C, A8344G, G8363A, T8993C, T8993G, T9176C, G13513A, T14709C), deletions, duplications |
PCR and ASO and/or RFLP and Southern blot hybridization |
2-3 weeks |
20 micrograms DNA (blood or muscle), muscle biopsy: 50 mg frozen |
|
CLIA |
1250; more than 25 samples a month 1150 |
Mitochondrial Panel 1 or 2 further investigations: MtDNA mutation quantitation |
|
mtDNA |
quantitate a single mtDNA Panel 1 point mutation or Panel 2 RFLP in additional family member |
PCR and ASO and/or RFLP |
2-3 weeks |
2 micrograms DNA |
|
CLIA |
345; more than 25 samples a month 300 |
Mitochondrial Panel 2 expanded : MNGIE (multiple mtDNA deletions); Ocular and skeletal myopathy + KSS; Pearson's marrow - pancreas syndrome; PEO |
530000, 557000 |
mtDNA |
deletions, duplications |
Southern blot hybridization |
2-3 weeks |
20 micrograms DNA (blood or muscle), muscle biopsy: 50 mg frozen |
|
CLIA |
625; more than 25 samples a month 575 |
Mitochondrial Panel 2 further investigations : Special sequencing |
|
mtDNA |
sequencing a limited region to identify change detected in Mitochondrial DNA Panel 2 |
Sequencing and PCR and RFLP |
2-3 weeks |
2 micrograms DNA |
|
CLIA |
345; more than 25 samples a month 300 |
Mitochondrial encephalopathy, lactic acidosis, stroke - like episodes,MELAS |
535000 |
mtDNA tRNA Leu |
|
|
|
2 micrograms muscle DNA |
|
|
290 |
Mitochondrial Panel 1 : MELAS; MERRF; NARP; Diabetes & deafness; Cardiomyopathy & deafness; Leigh syndrome |
516060, 520000, 540000, 545000, 551500, 590060 |
MTTL1, MTTE, MTTK, MTATP6, MTND5 |
A3243G, T3271C, A8344G, G8363A, T8993C, T8993G, T9176C, G13513A, T14709C |
PCR and ASO and/or RFLP |
2-3 weeks |
2 micrograms DNA (blood or muscle), muscle biopsy: 50 mg frozen |
|
CLIA |
725; more than 25 samples a month 675 |
Mitochondrial Panel 2 : MNGIE (multiple mtDNA deletions); Ocular and skeletal myopathy |
530000 |
mtDNA |
deletions |
Southern blot hybridization |
2-3 weeks |
20 micrograms DNA (blood or muscle), muscle biopsy: 50 mg frozen |
|
CLIA |
495; more than 25 samples a month 450 |
MLH1 Sequencing + MLPA |
114500 |
MLH1 |
whole gene |
Sequencing + MLPA |
6 weeks |
2 micrograms DNA |
ISO 15189 |
ISO 15189 |
950 |
MODY1 - Maturity Onset Diabetes of the Young, type 1 |
125850 |
HNF4 |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
EMQN 2006 |
ISO 17025:2005 / EMQN |
1300 |
MODY2 - Maturity Onset Diabetes of the Young, type 2 |
125851 |
GCK |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
EMQN 2006 |
ISO 17025:2005 / EMQN |
1300 |
MODY3 - Maturity Onset Diabetes of the Young, type 3 |
600496 |
TCF1 |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
EMQN 2006 |
ISO 17025:2005 / EMQN |
1300 |
Monilethrix |
158000 |
KRTHB1+ KRTHB6 |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
5450 |
Morbus Gilbert |
143500 |
UGT1A1 |
UGT1A1 6/ 7TA |
PCR, 12% PAGE, ETB |
3 weeks |
2 micrograms DNA |
DGKL (BRD) , ÚHKT (Prague - CZ) |
ISO 15189 |
110 |
Morning - Glory syndrome |
|
PAX6 |
P68S |
DNA extraction + amplification + sequence |
20 days |
2 micrograms DNA |
|
|
275 |
MSH6 Sequencing + MLPA |
600678 |
MSH6 |
whole gene |
Sequencing + MLPA |
6 weeks |
2 micrograms DNA |
ISO 15189 |
ISO 15189 |
880 |
MTHFR - A 1298C |
*607093 |
MTHFR |
A 1298C |
RT - PCR on Rotor - Gene 3000 (Corbett Reaserch) , CE kits (allelic discrimination) |
2 weeks |
2 micrograms DNA |
CSN EN ISO 15189 / ÚHKT (Prague - CZ) |
ISO 15189 |
55 |
Mucolipidosis type 4 |
252650 |
MCOLN1 |
IVS3-2A>3, 511del6434 |
RFLP |
3 weeks |
5 micrograms DNA |
NYS-DOH |
CLIA NYS-DOH CAP |
1-20 samples a month 135; 21-100 samples a month 115; over 100 samples a month 95 |
Muenke syndrome |
#602849 |
FGFR3 |
P250R |
DNA extraction + amplification + sequence |
20 days |
2 micrograms DNA |
|
|
240 |
Multiple drug resistance |
*171050 |
MDR1 |
C3435T |
Sequencing |
1 week |
2 micrograms DNA |
|
|
110 |
Multiple Endocrine Neoplasia |
131100 |
RET |
T918C |
RFLP's |
30 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
290 |
Multiple Endocrine Neoplasia |
131100 |
RET |
C634A |
RFLP's |
30 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
290 |
Multiple Endocrine Neoplasia |
131100 |
RET |
EXONS 10 AND 11 |
Sequencing |
30 days |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
4900 |
Multiple Endocrine Neoplasia |
131100 |
RET |
EXONS 13,14,16 |
Sequencing |
3 months |
2 micrograms DNA |
AEGH |
ISO 17025 EN PROCESS |
1390 |
Multiple Endocrine Neoplasia type 1 |
131100 |
MEN1 |
Sequencing (all coding exons) |
Sequencing (all coding exons) |
2 - 4 months |
2 micrograms DNA |
|
in preparation |
400 |
Multiple Endocrine Neoplasia type 2A |
171400 |
RET |
Sequencing (exon 10 and 11) |
Sequencing (exon 10 and 11) |
< 2 months |
2 micrograms DNA |
|
in preparation |
400 |
Multiple Endocrine Neoplasia type 2B |
162 300 |
RET |
Sequencing (exon 16) |
Sequencing (exon 16) |
< 2 months |
2 micrograms DNA |
|
in preparation |
400 |
Myocilin (MYOC) |
601652 |
TIGR, GLC1A |
Genomic Sequencing of the entire coding region |
Genomic Sequencing of the entire coding region |
2 - 4 weeks |
2 micrograms DNA |
|
DGKL,CAP |
1290 |
Myoclonus epilepsy, ragged red fibers , MERRF |
545000 |
mtDNA tRNA Lys |
|
|
|
2 micrograms muscle DNA |
|
|
290 |
Myotonia Congenita Autosomal Dominant |
#160800 |
CLCN1 |
all coding sequence |
polymerase chain reaction sequence analysis |
60 days |
4 micrograms DNA |
|
UNI EN ISO 9001 - CERMET / EMNQ, Istituto Superiore Sanità |
770 |
Myotonia Congenita Autosomal Recessive |
#105400 |
CLCN1 |
all coding sequence |
polymerase chain reaction sequence analysis |
60 days |
4 micrograms DNA |
|
UNI EN ISO 9001 - CERMET / EMNQ, Istituto Superiore Sanità |
770 |
Myotubular Myopathy (MTM1) |
#310400 |
Myotubularin |
all coding sequence |
polymerase chain reaction sequence analysis |
20 days |
4 micrograms DNA |
|
UNI EN ISO 9001 - CERMET / EMNQ, Istituto Superiore Sanità |
775 |
Nail - Patella syndrome |
161200 |
LMX1B |
all coding exons |
Sequencing |
30 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
1200 |
NARP - Neuropathy, ataxia, and retinitis pigmentosa |
551500 |
MTATP6 |
8993T>G y 8993TàC |
Sequencing |
20 days |
2 micrograms DNA |
|
ISO 17025:2005 / EMQN |
295 |
NAT2 |
243400 |
NAT2 |
NAT*5, NAT*6,NAT*7 |
PCR - RFLP |
2 weeks |
2 micrograms DNA |
|
CAP |
330 |
NAT2 genotyping |
243400 |
NAT2 |
all coding exons |
Sequencing |
20 days |
2 micrograms DNA |
|
|